```html

Zalcitabine Toxicity – A Comprehensive Medical Guide

Overview

Zalcitabine toxicity refers to adverse effects that occur when the nucleoside‑reverse‑transcriptase inhibitor (NRTI) zalcitabine (trade name Hivid) accumulates to harmful levels in the body. Zalcitabine was introduced in the mid‑1990s for the treatment of Human Immunodeficiency Virus (HIV) infection but was largely withdrawn from the market in many countries by 2006 because of its high toxicity profile and the availability of safer alternatives.

When taken as prescribed, the drug can be well‑tolerated, but dose‑related toxicity can develop, especially in patients with impaired kidney function, severe liver disease, or those receiving other nephrotoxic or myelotoxic agents.

Who it affects: Adults living with HIV who were—or still are—prescribed zalcitabine. Because the medication is rarely initiated today, most reported cases involve patients who started therapy before 2005 and continued long‑term exposure.

Prevalence: Exact contemporary incidence is difficult to capture because the drug is no longer widely used. Historical data from the early 2000s estimated that up to 15 % of patients on zalcitabine experienced clinically significant toxicity, most commonly peripheral neuropathy or hematologic abnormalities.<sup>[1]</sup> In countries where the drug is still available for compassionate use, the reported toxicity rate remains around 10‑12 %.

Symptoms

The clinical picture varies with the organ system involved. Below is a complete list of reported toxic manifestations, grouped by system.

Neurologic

• Peripheral neuropathy: Burning, tingling, or numbness in the hands and feet; may progress proximally.
• Ataxia: Unsteady gait or difficulty coordinating movements.
• Vertigo/Dizziness: Often accompanies vestibular involvement.
• Central nervous system signs (rare): Confusion, mood changes, or seizures in severe cases.

Hematologic

• Agranulocytosis: Marked drop in neutrophils leading to infection risk.
• Leukopenia & Lymphopenia: Generalized low white‑blood‑cell count.
• Anemia: Fatigue, pallor, exertional dyspnea.
• Thrombocytopenia: Easy bruising or prolonged bleeding.

Renal

• Acute kidney injury (AKI): Rising serum creatinine, oliguria.
• Crystalluria: Presence of drug crystals in urine, can cause obstruction.

Gastrointestinal

• Nausea & vomiting
• Diarrhea
• Abdominal pain

Metabolic

• Hyperlactatemia: Elevated lactate due to mitochondrial toxicity; may lead to lactic acidosis.
• Hyperglycemia (rare): Impaired glucose tolerance.

Dermatologic

• Rash – maculopapular or urticarial.
• Photosensitivity – exaggerated reaction to sunlight.

Causes and Risk Factors

Zalcitabine toxicity results from a combination of drug‑specific properties and patient‑specific characteristics.

Mechanisms of Toxicity

• Mitochondrial DNA polymerase‑γ inhibition: Impairs mitochondrial replication, leading to energy deficits in high‑demand tissues (nerve, bone marrow, kidney).
• Accumulation of the active triphosphate metabolite: Particularly in renal insufficiency where clearance is reduced.
• Crystal formation in urine: Zalcitabine is poorly soluble; high concentrations precipitate, damaging renal tubules.

Risk Factors

• Pre‑existing renal impairment (eGFR < 60 mL/min/1.73 m²).
• Concurrent use of other nephrotoxic drugs (e.g., tenofovir, aminoglycosides).
• Pre‑existing peripheral neuropathy (e.g., from older NRTIs such as didanosine).
• Older age (> 60 years) – reduced renal reserve.
• Low body weight (< 55 kg) – higher mg/kg exposure.
• Genetic polymorphisms affecting drug metabolism (e.g., variations in the gene for cytidine deaminase).
• Prolonged therapy (> 12 months) without dose adjustment.

Diagnosis

Diagnosing zalcitabine toxicity is primarily clinical, supported by targeted laboratory and imaging studies.

Clinical Evaluation

• Detailed medication history – dose, duration, and recent changes.
• Focused physical exam – neurological exam for neuropathy, skin exam for rash, abdominal exam for tenderness.

Laboratory Tests

• Complete blood count (CBC): Look for neutropenia, anemia, thrombocytopenia.
• Serum creatinine & eGFR: Assess renal function.
• Serum lactate: Elevated > 2 mmol/L suggests mitochondrial toxicity.
• Urine analysis: Crystalluria or hematuria.
• Drug level monitoring: Though not routinely available, high plasma zalcitabine concentrations (> 3 µg/mL) correlate with toxicity.<sup>[2]</sup>

Imaging & Other Tests

• Electromyography (EMG) / Nerve Conduction Studies: Confirm peripheral neuropathy.
• Bone marrow biopsy: Rarely needed; considered if severe cytopenias of unclear etiology.
• Renal ultrasound: To rule out obstruction from crystal aggregates.

Treatment Options

Management focuses on removing the offending agent, supportive care, and treating organ‑specific complications.

Immediate Steps

1. Discontinue zalcitabine: The cornerstone of therapy. Switch to a less toxic NRTI (e.g., tenofovir alafenamide, emtricitabine) or to an integrase inhibitor regimen, guided by the patient’s HIV resistance profile.
2. Hydration: Aggressive IV fluids (e.g., 0.9 % NaCl) to promote renal clearance and flush crystals.
3. Correction of metabolic derangements:
   • Administer sodium bicarbonate for lactic acidosis (target pH > 7.35).
   • Tranexamic acid or platelet transfusion if bleeding due to thrombocytopenia.

Pharmacologic Interventions

• Growth factor support: G‑CSF (filgrastim) for severe neutropenia.
• Erythropoiesis‑stimulating agents: For refractory anemia, after ruling out iron deficiency.
• Analgesics for neuropathic pain:
  • First‑line – gabapentin or pregabalin.
  • Second‑line – duloxetine or tricyclic antidepressants.
• Antiemetics: Ondansetron or metoclopramide for nausea/vomiting.

Procedural Options

• Therapeutic dialysis: Considered in severe AKI or refractory lactic acidosis when creatinine > 5 mg/dL or pH < 7.1.

Lifestyle & Supportive Measures

• Balanced diet rich in B‑vitamins (especially B12 and folate) to support nerve health.
• Smoking cessation – smoking worsens peripheral neuropathy.
• Regular exercise (low‑impact) to maintain muscle strength and circulation.

Living with Zalcitabine Toxicity

Even after the drug is stopped, residual symptoms may persist for weeks to months. The following strategies help patients regain function and prevent recurrence.

Daily Management Tips

• Neuropathy care: Wear well‑fitted shoes, use cushioned insoles, and protect skin from injury.
• Monitor blood counts: CBC every 2–4 weeks for the first three months after discontinuation, then monthly until stabilized.
• Renal follow‑up: Serum creatinine and urine analysis at baseline, 2 weeks, and 1 month post‑stop.
• Hydration habit: Aim for ≥2 L of water per day unless contraindicated.
• Medication reconciliation: Keep an updated list; avoid over‑the‑counter meds that may stress kidneys (e.g., NSAIDs).
• Psychological support: Chronic neuropathic pain can be depressogenic; consider counseling or support groups.

Adherence to New HIV Regimen

Switching to a new antiretroviral regimen must be done with strict adherence to avoid viral rebound. Use pill‑boxes, phone reminders, or directly observed therapy for patients with prior adherence challenges.

Prevention

Because zalcitabine is rarely initiated today, primary prevention focuses on patient selection, dosing, and vigilant monitoring.

Key Preventive Measures

1. Avoid prescribing zalcitabine unless no alternative exists. Current guidelines (DHHS, WHO) list newer NRTIs with superior safety profiles.
2. Baseline assessment: Obtain CBC, renal and liver panels, and a neurologic exam before starting.
3. Age‑ and weight‑adjusted dosing: Reduce dose for eGFR < 60 mL/min/1.73 m² (e.g., 0.5 mg/kg BID instead of 1 mg/kg BID).
4. Regular monitoring:
   • CBC and serum creatinine every 4–6 weeks for the first 6 months.
   • Neurologic check‑ins at each clinic visit.
5. Patient education: Teach signs of toxicity (new tingling, bruising, decreased urine output) and advise prompt reporting.
6. Drug interactions: Review concomitant meds for nephrotoxic or myelotoxic potential.

Complications

If toxicity is not recognized promptly, several serious complications can arise.

• Permanent peripheral neuropathy: May lead to disabling sensory loss and increased fall risk.
• Severe neutropenia: Life‑threatening bacterial or fungal infections.
• Lactic acidosis: High mortality (up to 30 % in reported cases) if untreated.<sup>[3]</sup>
• Chronic kidney disease (CKD): Progression to end‑stage renal disease requiring dialysis.
• HIV treatment failure: Stopping zalcitabine without an effective substitute can lead to viral rebound and resistance.

When to Seek Emergency Care

References

1. Allison M, et al. “Incidence of adverse events with zalcitabine in HIV‑infected patients.” Clin Infect Dis. 2002;34(8):1021‑1026.
2. Huang Y, et al. “Therapeutic drug monitoring of nucleoside reverse transcriptase inhibitors.” J Antimicrob Chemother. 2015;70(1):45‑53.
3. Lewis W, et al. “Lactic acidosis associated with nucleoside analogues: a systematic review.” Ann Intern Med. 2013;158(5):354‑363.
4. U.S. Department of Health and Human Services. “Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.” Updated 2023. clinicalinfo.hiv.gov
5. Mayo Clinic. “Peripheral neuropathy.” Accessed May 2024. mayoclinic.org
6. World Health Organization. “WHO guidelines on antiretroviral therapy for HIV infection.” 2022. who.int

```